drugset / Trial / NCT04295447
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Phase 2
Active not recruiting
190 enrolled
University of Münster
Janssen Pharmaceutica N.V., Belgium · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to standard of care (SOC).
Timeline
- Start
- 2020-12-10
- Primary completion
- 2028-11-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | 240 mg | — |